Agios Pharmaceuticals, Inc. (AGIO) Deep Dive Video

Summary

Agios is a well-funded rare-disease inflection story where Aqvesme’s thalassemia launch could transform revenue, but SCD competition and REMS execution will determine the scale of upside.

View AGIO stock page · Read the AGIO research report

Loading the video player…